Tegsedi™ to be Available on the NHS for hATTR Amyloidosis | oneAMYLOIDOSISvoice

Tegsedi™ to be Available on the NHS for hATTR Amyloidosis

Akcea Therapeutics UK Ltd., has announced that NICE has issued a positive Final Evaluation Document (FED) for Tegsedi™ (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). This decision will allow patients in England with this rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.
hATTR amyloidosis is a severe, progressive, and life-threatening disease caused by the abnormal formation of the TTR protein and aggregation of TTR amyloid deposits in various tissues and organs throughout the body, including in peripheral nerves, the heart and intestinal tract. The progressive accumulation of TTR amyloid deposits in these organs often leads to intractable peripheral sensorimotor neuropathy, autonomic neuropathy, and/or cardiomyopathy, as well as other disease manifestations.
Tegsedi™ To Be Available On The NHS For HATTR Amyloidosis

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.